Negative inotropic and chronotropic effects of δ-opioid receptor antagonists are mediated via non-opioid receptors

Bulletin of Experimental Biology and Medicine

Volumn 141, Issue 4, 2006, Pages 420-423

  Maslov, L N ^a,b   Lishmanov, Yu B ^a   Barzakh, E I ^a,b   Lasukova, T V ^a   Rice, K K ^c   Oeltgen, P R ^d  

^a Russian Academy of Medical Sciences   (Russian Federation)

^b TOMSK STATE PEDAGOGICAL UNIVERSITY   (Russian Federation)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

opioid receptor antagonists; Cardiac rhythm; Isolated perfused heart

Indexed keywords

1,2,3,4,4A,5,12,12AALPHA OCTAHYDRO 4AALPHA (3 HYDROXYPHENYL) 2 METHYLQUINOLINO[2,3 G]ISOQUINOLINE; DELTA OPIATE RECEPTOR AGONIST; DELTA OPIATE RECEPTOR ANTAGONIST; DELTORPHIN; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; N,N DIALLYLTYROSYL 2 METHYLALANYL 2 METHYLALANYLPHENYLALANYLLEUCINE; NALOXONE; NALTREXONE; NALTRINDOLE; OPIATE RECEPTOR;

ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CHRONOTROPISM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; HEART CONTRACTION; HEART LEFT VENTRICLE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE RELAXATION; HEART PERFUSION; HEART RATE; IN VITRO STUDY; IN VIVO STUDY; INJECTION; INOTROPISM; ISOLATED HEART; NONHUMAN; RAT; RECEPTOR INTRINSIC ACTIVITY;

ANIMALS; BLOOD PRESSURE; CARDIOTONIC AGENTS; LIGANDS; MYOCARDIAL CONTRACTION; MYOCARDIUM; NALOXONE; NALTREXONE; PERFUSION; RATS; RATS, WISTAR; RECEPTORS, OPIOID; RECEPTORS, OPIOID, DELTA; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33746551667     PISSN: 00074888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10517-006-0188-y     Document Type: Article

References (15)

1. T. V. Lasukova, L. N. Maslov, Yu. K. Podoksenov, et al., Byull. Eksp. Biol., 137, No. 1, 35-38 (2004).
2. Yu. B. Lishmanov and L. N. Maslov, Pat. Fiziol. Eksp. Ter., No. 1, 2-10 (2003).
3. L. N. Maslov, Yu. B. Lishmanov, G. Calo, and L. Ma, Ibid., 66, No. 5, 59-68 (2003).
4. L. N. Maslov, Yu. B. Lishmanov, and G. N. Smagin, Eksp. Klin. Farmakol., 65, No. 2, 70-75 (2002).
5. E. V. Navolotskaya, Yu. A. Kovalitskaya, Yu. A. Zolotarev, et al., Biokhimiya, 69, No. 8, 1071-1078 (2004). 1071-1078 (2004).
6. J. L. Butour, C. Moisand, H. Mazarguil, et al., Eur. J. Pharmacol., 321, No. 1, 97-103 (1997).
7. T. Costa and A. Herz, Proc. Natl. Acad. Sci. USA, 86, 7321-7325 (1989).
8. B. N. Dhawan, F. Cesselin, R. Raghubir, et al., Pharmacol. Rev., 48, No. 4, 567-592 (1996).
9. M. Dumont and S. Lemaire, J. Mol. Cell. Cardiol., 30, No. 12, 2751-2760 (1998).
10. P. J. Emmerson, M. R. Liu, J. H. Woods, and F. Medzihradsky, J. Pharmacol. Exp. Ther., 271, No. 3, 1630-1637 (1994).
11. L. N. Maslov, Yu. B. Lishmanov, N. V. Solenkova, et al., Life Sci., 73, No. 7, 947-952 (2003).
12. R. J. Milne, J. M. Coddington, and G. D. Gamble, Neurosci. Lett., 114, No. 3, 250-264 (1990).
13. B. P. Roques, G. Gacel, V. Dauge, et al., Neurophysiol. Clin., 20, No. 5, 369-387 (1990).
14. G. E. Sander, R. F. Lowe, and T. O. Giles, Peptides, 7, No. 2, 259-265 (1986).
15. C. Ventura, L. Bastagli, P. Bernardi, et al., Biochem. Biophys. Acta, 987, No. 1, 69-74 (1989).